Increasing the rate of dry eye treatment can improve outcomes, generate more revenue

McDonald, Marguerite B.
February 2011
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p16
Academic Journal
The article focuses on dry eye treatment, wherein it is said that increasing its rate may enhance surgical outcomes and quality of life, and increased business opportunity for ophthalmology practice.


Related Articles

  • Age, refractive index of corneal stroma help improve LASIK predicted outcomes. Fox, Christi; Hasson, Matt // Ocular Surgery News;6/25/2013, Vol. 31 Issue 12, p24 

    The article reports on the findings of a research which revealed how taking into account patient age and refractive index of the corneal stroma into the treatment profile enhanced the predictability of LASIK surgery outcomes.

  • Short-Term Effects of Instillation of a Rebamipide Suspension on Visual Function. Kaido, Minako; Ishida, Reiko; Dogru, Murat; Tsubota, Kazuo // Journal of Ocular Pharmacology & Therapeutics;May2014, Vol. 30 Issue 4, p313 

    Purpose: To investigate the short-term adverse effects of using rebamipide for the treatment of dry eye by assessing visual function and optical quality. Methods: This interventional noncomparative study included 14 right eyes of 14 healthy volunteers. Serial measurements of visual acuity (VA)...

  • Patient age correlates with postoperative refractive outcomes in highly myopic eyes.  // Ocular Surgery News;5/25/2013, Vol. 31 Issue 10, p25 

    The article discusses research on the correlation between patient age and postoperative refractive outcomes in highly myopic eyes, published in a 2013 issue of the "Journal of Cataract and Refractive Surgery."

  • Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study. Lipton, RB; Manack, AN; Serrano, D; Buse, DC // Journal of Headache & Pain;Feb2013 Supplement, Vol. 14, p1 

    An abstract of the article " Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study" by R. B. Lipton, A. N. Manack, D. Serrano and D. C. Buse is presented.

  • Addressing punctal occlusion and tear osmolarity correlation in dry eye. Guttman Krader, Cheryl; Pepose, Jay S. // Ophthalmology Times;6/ 1/2014, Vol. 39 Issue 11, p26 

    The article discusses the impact of punctal occlusion and tear osmolarity correlation on treating dry eye, which was supported by a prospective pilot study participated by 15 patients with baseline tear osmolarity. Topics discussed include the results of the study that found significant...

  • Training Clinical Officers in Tubal Ligation May Help Meet Rural Ugandan Women's Need for Sterilization. Ramashwar, S. // International Perspectives on Sexual & Reproductive Health;Mar2014, Vol. 40 Issue 1, p48 

    The article reports on a study that was designed to examine whether clinical officers can safely perform tubal ligation in rural Uganda, where there is a short supply of physicians. Topics discussed include the lack of health care providers in the area resulted in high unmet need for...

  • Autologous serum drops relieve dry eye over long term. Kronemyer, Bob // Ocular Surgery News;1/25/2015, Vol. 33 Issue 2, p22 

    The article reports that 50 percent autologous serum drops can be used to treat patients of dry eye disease who have not be relieved by standard medical treatments such as lubricating eye drops, ophthalmic emulsion and steroids. Topics discussed includes efficacy of autologous serum drops in...

  • Femtosecond intrastromal keratotomy reduces astigmatism after LASIK, PRK. Hasson, Matt // Ocular Surgery News;3/10/2013, Vol. 31 Issue 5, p9 

    The article reports a study which revealed intrastromal femtosecond laser astigmatic keratotomy to be safe and feasible method of correcting low to moderate astigmatism after previous refractive surgery. In addition, the reduction of astigmatism was greater among patients who had previously...

  • Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. Plosker, Greg // Drugs;Mar2014, Vol. 74 Issue 4, p451 

    Rivaroxaban (Xarelto) is an orally administered highly selective direct inhibitor of factor Xa that has been approved in many countries to reduce the risk of stroke in patients with atrial fibrillation and for the treatment and prevention of venous thromboembolism. More recently, rivaroxaban at...


Read the Article


Sign out of this library

Other Topics